Three-dimensional ultrasonography to assess long-term durability of periurethral collagen in women with stress urinary incontinence due to intrinsic sphincter deficiency
- PMID: 15667864
- DOI: 10.1016/j.urology.2004.08.034
Three-dimensional ultrasonography to assess long-term durability of periurethral collagen in women with stress urinary incontinence due to intrinsic sphincter deficiency
Abstract
Objectives: To investigate the natural history of periurethral collagen injection (PCI) over time using serial three-dimensional ultrasonography (3DUS) of the urethra as an objective measure.
Methods: Retrospective chart review was performed for all patients who underwent PCI between February 1999 and February 2003. All had been diagnosed with stress urinary incontinence due to intrinsic sphincter deficiency without urethral hypermobility, had follow-up data including two or more 3DUS scans within 1 year or more, and had undergone no additional PCIs (ie, remained clinically improved). The follow-up examinations included serial history, symptom and quality-of-life (QOL) questionnaires (Urogenital Distress Inventory, global QOL visual analog scale [scale of 0 to 10, with 0 = best]), physical examination, and 3DUS scans. The primary subjective and objective outcomes were the Urogenital Distress Inventory and QOL scores and the 3DUS-determined periurethral collagen volume and configuration, respectively.
Results: Of the 54 patients undergoing PCI during the accrual period, 20 had follow-up of 1 year or longer (mean 2.0, range 1 to 3.8). The mean 3DUS collagen volumes were not statistically different at baseline at a mean of 4 months after PCI (2.9 +/- 1.9 cm3) compared with at the last follow-up visit (2.7 +/- 1.9 cm3; P = 0.34). The volume retention rate was 97% +/- 33% of the baseline volume. The periurethral configuration was circumferential in 80% and asymmetric in 20%, and was maintained over time. The postinjection Urogenital Distress Inventory question 3 (stress urinary incontinence) and QOL scores were significantly improved compared with the pre-PCI evaluations with a mean of 2.4 +/- 0.8 versus 1.4 +/- 0.7 (P = 0.013) and 7.3 +/- 2.6 versus 3.5 +/- 2.5 (P = 0.001), respectively.
Conclusions: This is the first study to demonstrate the long-term durability of PCI on serial 3DUS in association with improved continence and QOL using questionnaire analysis. This new knowledge provides a technical and therapeutic endpoint for PCI.
Similar articles
-
Is there a role for periurethral collagen injection in the management of urodynamically proven mixed urinary incontinence?Urology. 2006 Apr;67(4):725-9; discussion 729-30. doi: 10.1016/j.urology.2005.10.066. Urology. 2006. PMID: 16618559
-
Collagen injection for female urinary incontinence after urethral or periurethral surgery.J Urol. 2009 Feb;181(2):701-4. doi: 10.1016/j.juro.2008.10.027. Epub 2008 Dec 16. J Urol. 2009. PMID: 19091340
-
Durability of collagen injection for stress urinary incontinence in women proven by transvaginal 3-dimensional ultrasound.Female Pelvic Med Reconstr Surg. 2015 Jan-Feb;21(1):25-9. doi: 10.1097/SPV.0000000000000094. Female Pelvic Med Reconstr Surg. 2015. PMID: 25185619
-
Role of three-dimensional ultrasound in assessment of women undergoing urethral bulking agent therapy.Curr Opin Obstet Gynecol. 2004 Oct;16(5):411-7. doi: 10.1097/00001703-200410000-00010. Curr Opin Obstet Gynecol. 2004. PMID: 15353951 Review.
-
Followup of intraurethral collagen for female stress urinary incontinence.J Urol. 1996 Oct;156(4):1305-9. J Urol. 1996. PMID: 8808860 Review.
Cited by
-
Urethral bulking agents: techniques and outcomes.Curr Urol Rep. 2009 Sep;10(5):396-400. doi: 10.1007/s11934-009-0062-3. Curr Urol Rep. 2009. PMID: 19709488 Review.
-
Macroplastique for women with stress urinary incontinence secondary to intrinsic sphincter deficiency.Int Braz J Urol. 2019 Sep-Oct;45(5):989-998. doi: 10.1590/S1677-5538.IBJU.2019.0070. Int Braz J Urol. 2019. PMID: 31626522 Free PMC article.
-
Patient-perceived outcomes in the treatment of stress urinary incontinence: focus on urethral injection therapy.Int Urogynecol J Pelvic Floor Dysfunct. 2007 Feb;18(2):199-205. doi: 10.1007/s00192-006-0148-0. Epub 2006 Jul 18. Int Urogynecol J Pelvic Floor Dysfunct. 2007. PMID: 16847584 Review.
-
Combined trans- and periurethral injections of bulking agents for the treatment of intrinsic sphincter deficiency.Int Urogynecol J Pelvic Floor Dysfunct. 2008 May;19(5):643-7. doi: 10.1007/s00192-007-0493-7. Epub 2007 Oct 27. Int Urogynecol J Pelvic Floor Dysfunct. 2008. PMID: 17965815
-
Durasphere® EXP: a non-biodegradable agent for treatment of primary Vesico-Ureteral reflux in children.Int Braz J Urol. 2018 May-Jun;44(3):585-590. doi: 10.1590/S1677-5538.IBJU.2017.0514. Int Braz J Urol. 2018. PMID: 29522294 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous